

University of Groningen

First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner

Brouwers, Adrienne H; van Sluis, Joyce; van Snick, Johannes H; Schröder, Carolina P; Baas, Inge O; Boellaard, Ronald; Glaudemans, Andor W J M; Borra, Ronald J H; Lammertsma, Adriaan A; Dierckx, Rudi A J O

Published in:

European Journal of Nuclear Medicine and Molecular Imaging

DOI:

[10.1007/s00259-022-05777-x](https://doi.org/10.1007/s00259-022-05777-x)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Brouwers, A. H., van Sluis, J., van Snick, J. H., Schröder, C. P., Baas, I. O., Boellaard, R., Glaudemans, A. W. J. M., Borra, R. J. H., Lammertsma, A. A., Dierckx, R. A. J. O., & Tsoumpas, C. (2022). First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner. *European Journal of Nuclear Medicine and Molecular Imaging*, 49, 3593-3595. <https://doi.org/10.1007/s00259-022-05777-x>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



First-time imaging of [⁸⁹Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner

Adrienne H. Brouwers¹ · Joyce van Sluis¹ · Johannes H. van Snick¹ · Carolina P. Schröder^{1,2} · Inge O. Baas³ · Ronald Boellaard^{1,4} · Andor W. J. M. Glaudemans¹ · Ronald J. H. Borra¹ · Adriaan A. Lammertsma¹ · Rudi A. J. O. Dierckx¹ · Charalampos Tsoumpas¹

Received: 3 February 2022 / Accepted: 19 March 2022
© The Author(s) 2022

Long axial field-of-view (LAFOV) PET/CT scanners have been introduced recently [1, 2], which offer numerous advantages [3]. One important advantage of using LAFOV PET/CT for imaging ⁸⁹Zr-labelled monoclonal antibodies (mAbs), i.e., immunoPET, is the substantial increase in sensitivity compared with standard axial field-of-view (SAFOV) PET/CT systems, which may lead to a remarkable image quality improvement. This first study showcases such improvement for immunoPET with Biograph Vision Quadra™ (VQ) LAFOV PET/CT (Siemens Healthineers, Knoxville, TN, USA).

Two patients suffering from metastatic HER2-positive breast cancer were administered with 37 MBq [⁸⁹Zr]trastuzumab in order to assist clinical decision-making [4, 5]. Patients were scanned 4 days postinjection with a Biograph™ mCT PET/CT (patient A) or a Biograph Vision™ PET/CT (patient B) (Siemens Healthineers, Knoxville, TN, USA), according to local standard operating procedures with overall scan durations of 45 min and 32 min, for, respectively, mCT and Vision. Following

the clinical scans, patients were scanned with VQ. For VQ, we choose to apply a long scan duration of 30 min (patient A) and 32 min (patient B) to improve image quality rather than shortening the overall scan duration, as compared to Vision. For SAFOV systems, the acquisition and reconstruction parameters complied with EARL1, whilst for LAFOV, we also applied clinically (CLIN) recommended settings (Table 1) [6, 7].

PET/CT images of patient A are shown in the top two rows (a-h), for patient B in the bottom rows (i-p). The same intensity scale, SUV range 0–10, applies for all images, except the fused images (e, m). Additional reconstructions of the Vision Quadra data were obtained, mimicking 3-min (d, h, l, p) and 10-min (c, g, k, o) acquisitions, illustrating more pragmatic scan durations.

As can be appreciated from these first human immunoPET images on a LAFOV system, the image quality improvement (f) is most spectacular when compared with the mCT (a). For example, in patient A, an additional small bone lesion was visualized with VQ in the pelvic area (f), which was not visible with the SAFOV system (a). Even when compared to the Vision (i), the VQ image (n) shows improved quality without applying any filter after reconstruction. Moreover, this image quality was improved even in the 10 min image compared with the 30–45 min acquisition needed for SAFOV systems.

Thus, this image shows that the large axial FOV system provides substantial improvement in image quality when applying currently preferred overall scan durations on SAFOV systems (45 min for mCT, 32 min for Vision). Additionally, with the new LAFOV system, there is room for further reduction of the overall scan duration with still very acceptable image quality, even for ⁸⁹Zr-labelled mAb PET/CT studies.

This article is part of the Topical Collection on Image of the month


✉ Adrienne H. Brouwers
a.h.brouwers@umcg.nl

- ¹ University of Groningen, University Medical Center Groningen, Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, PO Box 30001, 9700 RB Groningen, The Netherlands
- ² Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, The Netherlands
- ³ University of Utrecht, University Medical Center Utrecht, Department of Medical Oncology, Utrecht, The Netherlands
- ⁴ VU Amsterdam, Amsterdam UMC - Location VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands

Table 1 Acquisition and reconstruction parameters for the different systems

PET/CT system	Acquisition method	Reconstruction protocol name	Reconstruction settings
Biograph mCT	Step and shoot: 5 min per bed position (bp), 9 bp	EARL1	OSEM, 3i21s, size $256 \times 256 \times 488$, voxel size $3.2 \times 3.2 \times 2.0 \text{ mm}^3$, 6.5 mm FWHM Gaussian filter
Biograph Vision	Flow: continuous bed motion, 8 min per body pass, 4 passes	EARL1	OSEM, 4i5s, size $220 \times 220 \times 706$, voxel size $3.3 \times 3.3 \times 1.5 \text{ mm}^3$, 7 mm FWHM Gaussian filter
Biograph Vision Quadra	Single bp	EARL1	OSEM, 4i5s, size $220 \times 220 \times 708$, voxel size $3.3 \times 3.3 \times 1.5 \text{ mm}^3$, 7 mm FWHM Gaussian filter
	Single bp	CLIN	OSEM, 4i5s, size $440 \times 440 \times 708$, voxel size $1.6 \times 1.6 \times 1.5 \text{ mm}^3$, no filtering

EARL European Association of Nuclear Medicine Research Ltd., OSEM 3D ordered subset expectation maximization with time-of-flight and point spread function, *i* iterations, *s* subsets, FWHM full width at half maximum



Author contribution All authors read and approved the final manuscript.

Declarations

Ethics approval and consent to participate The medical Ethics Review Board of the University Medical Center Groningen waived the need for formal ethical review of the validation protocol of the Vision Quadra PET/CT system (waiver number METc2020/554). Both patients were informed about the study aims, procedures (one additional PET/CT scan on the same day with the planned PET/CT), and the need to acquire an additional low-dose CT scan. Informed consent was obtained before the start of the second acquisition on the LAFOV PET/CT system.

Consent for publication Both patients gave written informed consent to anonymously use their clinical and imaging data for publication.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, et al. First human imaging studies with the EXPLORER total-body PET scanner. *J Nucl Med.* 2019;60:299–303.
2. Prenosil GA, Sari H, Fürstner M, Afshar-Oromieh A, Shi K, Rominger A, et al. Performance characteristics of the Biograph Vision Quadra PET/CT system with long axial field of view using the NEMA NU 2–2018 standard. *J Nucl Med.* 2022;63:476–84.

3. Slart RHJA, Tsoumpas C, Glaudemans AWJM, Noordzij W, Willemsen ATM, Borra RJH, et al. Long axial field of view PET scanners: a road map to implementation and new possibilities. *Eur J Nucl Med Mol Imaging*. 2021;48:4236–45.
4. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, De Jong JR, et al. Biodistribution of ^{89}Zr -trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. *Clin Pharmacol Ther*. 2010;87:586–92.
5. Bensch F. ^{89}Zr -trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. *Eur J Nucl Med Mol Imaging*. 2018;45:2300–6.
6. Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *Eur J Nucl Med Mol Imaging*. 2015;42:328–54.
7. Kaalep A, Huisman M, Sera T, Vugts D, Boellaard R. Feasibility of PET/CT system performance harmonisation for quantitative multicentre ^{89}Zr studies. *EJNMMI Phys*. 2018;5:26.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.